1. Home
  2. PCRX vs DK Comparison

PCRX vs DK Comparison

Compare PCRX & DK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • DK
  • Stock Information
  • Founded
  • PCRX 2006
  • DK 2001
  • Country
  • PCRX United States
  • DK United States
  • Employees
  • PCRX N/A
  • DK N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • DK Integrated oil Companies
  • Sector
  • PCRX Health Care
  • DK Energy
  • Exchange
  • PCRX Nasdaq
  • DK Nasdaq
  • Market Cap
  • PCRX 1.1B
  • DK 1.0B
  • IPO Year
  • PCRX 2011
  • DK 2006
  • Fundamental
  • Price
  • PCRX $24.91
  • DK $15.67
  • Analyst Decision
  • PCRX Buy
  • DK Sell
  • Analyst Count
  • PCRX 9
  • DK 10
  • Target Price
  • PCRX $30.67
  • DK $20.56
  • AVG Volume (30 Days)
  • PCRX 920.6K
  • DK 1.7M
  • Earning Date
  • PCRX 05-06-2025
  • DK 05-06-2025
  • Dividend Yield
  • PCRX N/A
  • DK 6.50%
  • EPS Growth
  • PCRX N/A
  • DK N/A
  • EPS
  • PCRX N/A
  • DK N/A
  • Revenue
  • PCRX $700,966,000.00
  • DK $11,852,200,000.00
  • Revenue This Year
  • PCRX $9.77
  • DK N/A
  • Revenue Next Year
  • PCRX $9.83
  • DK N/A
  • P/E Ratio
  • PCRX N/A
  • DK N/A
  • Revenue Growth
  • PCRX 3.85
  • DK N/A
  • 52 Week Low
  • PCRX $11.16
  • DK $13.40
  • 52 Week High
  • PCRX $31.67
  • DK $33.60
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 55.86
  • DK 45.42
  • Support Level
  • PCRX $23.93
  • DK $15.38
  • Resistance Level
  • PCRX $25.08
  • DK $16.58
  • Average True Range (ATR)
  • PCRX 0.97
  • DK 0.84
  • MACD
  • PCRX 0.20
  • DK 0.13
  • Stochastic Oscillator
  • PCRX 76.05
  • DK 51.95

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About DK Delek US Holdings Inc.

Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. Delek's logistics segment sells portions of the petroleum products its refineries produce. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.

Share on Social Networks: